PharmAla receives MDMA research grant from Ontario Centre of Innovation
June 12, 2023Research and Development MDMA, PharmAla, Psychiatry, in silico, research grant
Canadian biotechnology company PharmAla has announced that it has been awarded a research grant from the Ontario Centre of Innovation …
Novartis acquires Chinook Therapeutics for $3.5bn
June 12, 2023Mergers and Acquisitions Chinook Therapeutics, Nephrology, Novartis, kidney disease, pharma
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based biopharmaceutical company Chinook Therapeutics for …
AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment
June 9, 2023Research and Development AstraZeneca, Cancer, MSD, NICE, Oncology, lynparza, pharma
UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) posted a positive recommendation …
Astellas Pharma and BMT CTN announce phase 3 data for gilteritinib
June 9, 2023Research and Development Astellas Pharma, BMT CTN, Haematology, gilteritinib, leukaemia, pharmaceutical
Japanese pharmaceutical company Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) have presented their phase …
Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation
June 8, 2023Research and Development Cancer, FDA, Haematology, Innate Pharma, Sanofi, haematology
Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US Food and Drug Administration (FDA) …
Inventiva and Echosens collaborate to bring awareness to NASH and encourage screening for at-risk patients
June 8, 2023Medical Education Echosens, Hepatology, Inventiva, liver disease, nash, non-alcoholic steatohepatitis
French clinical stage biopharmaceutical company Inventiva has announced a collaboration with US-based high-technology company Echosens to bring attention to, and …
Inizio launches strategic engagement offering to transform customer experiences
June 7, 2023Business Services Inizio, Inizio Engage, commercialisation
6 June 2023 – London, UK — Inizio, a global commercialisation partner dedicated to the health and life sciences industry, …
Fosun Pharma and IFC partner to improve access to medicines in Africa
June 7, 2023Manufacturing and Production Africa, Fosun Pharma, IFC, Infections and infestations, manufacturing
Shanghai Fosun Pharmaceutical Group has announced a partnership with the International Finance Corporation (IFC) with the aim of helping the …
GSK’s RSV vaccine approved in EU for older adults
June 7, 2023Medical Communications EU, GSK, Infections and infestations, RSV, Vaccine
GSK has announced that the European Commission (EC) has authorised Arexvy, the company’s respiratory syncytial virus (RSV) vaccine for active …
Axol Bioscience and StrataStem collaborate to deliver ‘clinical trial in a dish’ for Alzheimer’s disease
June 7, 2023Research and Development Alzheimer's, Axol Bioscience, Neurology, StrataStem
Pluripotent stem cell technology provider Axol Bioscience has signed an exclusive agreement with UK-based StrataStem to access and commercialise its …
UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity
June 7, 2023Research and Development NHS, Novo Nordisk, Obesity, Wegovy, clinical trial, obesity
The UK Government has announced plans to launch a pilot programme which will provide GPs with Novo Nordisk’s Wegovy (semaglutide), …
GRAIL and University of Oxford showcase first prospective study results for multi-cancer early detection test
June 6, 2023Research and Development Cancer, GRAIL, Oncology, University of Oxford, cancer testing
US-based healthcare company GRAIL and the University of Oxford, UK, have announced encouraging first prospective study results at the American …
ISA Pharmaceuticals highlights positive clinical data at ASCO
June 6, 2023Research and Development ASCO, Cancer, HPV, ISA Pharmaceuticals, Oncology
Clinical stage biotechnology company ISA Pharmaceuticals has announced positive phase 1 data at the American Society of Clinical Oncology (ASCO) …
Bellerophon shares top-line data from phase 3 trial of INOpulse for fILD
June 6, 2023Medical Communications Bellerophon Therapeutics, Cardiology, clinical trials, fibrotic interstitial lung disease
Bellerophon Therapeutics has announced top-line results from its phase 3 REBUILD trial evaluating the safety and efficacy of INOpulse for …
GSK receives FDA file acceptance for Jemperli plus chemotherapy for treating endometrial cancer
June 6, 2023Research and Development GSK, Jemperli, Oncology, endometrial cancer, oncology
GSK has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …
AstraZeneca’s phase 4 trial stopped early after reaching pre-specified criteria
June 5, 2023Research and Development ANNEXA-I, Andexxa, AstraZeneca, Neurology, clinical trial
AstraZeneca has announced that its post-marketing phase 4 ANNEXA-I trial has been stopped early after reaching its pre-specified stopping criteria. …
Quanticate announces strategic partnership with KPS Life
June 5, 2023Medical Communications KPS Life, Pharmacy, Quanticate, fsp
Global biometric clinical research group Quanticate has announced a strategic partnership with US-based provider of functional service provision (FSP) solutions …
Allogene Therapeutics shares updated ALLO-501/501A phase 1 data in large B-cell lymphoma at ASCO annual meeting
June 5, 2023Research and Development Allogene, LBCL, Oncology, lymphoma, oncology
Allogene Therapeutics has shared updated data from the phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large …
Report finds NHS may miss out on new drugs due to rising costs
June 5, 2023Sales and Marketing LSE, LSHTM, NHS, Pharmacy, University of York, drug prices
Figures from a team at the University of York, the London School of Economics and Political Science (LSE) and the …
NICE approves first treatment for obstructive HCM for NHS use
June 2, 2023Medical Communications Bristol-Myers Squibb, Cardiology, NHS, NICE, obstructive HCM
The National Institute for Health and Care Excellence (NICE) has announced that it has approved mavacamten (Camzyos) for the treatment …
Latest content
FibroFind appoints Lee Borthwick as CEO
